 |
|
High-Dose Intravenous Immunoglobulin in the Management of Myasthenia Gravis
Edward L. Arsura, MD;
Aaron Bick, MD;
Norman G. Brunner, MD;
Tatsuji Namba, MD, PhD;
David Grob, MD
Arch Intern Med. 1986;146(7):1365-1368.
Abstract
| |
• Intravenous immunoglobulin, 400 mg/kg, was administered daily for five days to 12 patients with exacerbation of generalized myasthenia gravis. Degree of weakness, duration of illness, use of prednisone, and history of thymectomy or thymoma did not affect the response to intravenous immunoglobulin. Eleven patients improved, beginning 3.6±2.7 (mean ± SD) days after the start of treatment and becoming maximal in 8.6±4.6 days, with sustained improvement lasting 52 ±37 days. Vital capacity increased from 1748 ±510 to 2700 ± 614 mL at peak effect. Decreases in strength occurred in four patients beginning on day 3.2 ±2.5, lasted 1.5 ±0.6 days, and were mild in three patients. Other effects were minimal. There was no significant change in acetylcholine receptor antibody titers, which were elevated in all patients. Immunoglobulin seemed to produce a more rapid improvement than corticosteroids and is recommended as an adjunct in the management of myasthenia gravis exacerbations.
(Arch Intern Med 1986;146:1365-1368)
Author Affiliations
From the Departments of Medicine, State University of New York Downstate Medical Center and Maimonides Medical Center, Brooklyn, NY.
Footnotes
Accepted for publication Oct 11, 1985.
Reprint requests to Department of Medicine, Maimonides Medical Center, 4802 Tenth Ave, Brooklyn, NY 11219 (Dr Arsura).
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Treatment of autoimmune myasthenia gravis
Richman and Agius
Neurology 2003;61:1652-1661.
ABSTRACT
| FULL TEXT
Immunoadsorption as a new therapeutic principle for treatment of dilated cardiomyopathy
Felix et al.
Eur Heart J Suppl 2002;4:I63-I68.
ABSTRACT
Hemodynamic effects of immunoadsorption and subsequent immunoglobulin substitution in dilated cardiomyopathy: Three-month results from a randomized study
Felix et al.
J Am Coll Cardiol 2000;35:1590-1598.
ABSTRACT
| FULL TEXT
Intravenous Immunoglobulin Treatment in Neurologic Disorders: Yes
Sorensen
Arch Neurol 1999;56:1025-1027.
FULL TEXT
Myasthenic Crisis: Response to Plasmapheresis Following Failure of Intravenous {gamma}-Globulin
Stricker et al.
Arch Neurol 1993;50:837-840.
ABSTRACT
Open Controlled Therapeutic Trial of Intravenous Immune Globulin in Relapsing-Remitting Multiple Sclerosis
Achiron et al.
Arch Neurol 1992;49:1233-1236.
ABSTRACT
Clinical Uses of Intravenous Immunoglobulins
Berkman et al.
ANN INTERN MED 1990;112:278-292.
ABSTRACT
High-Dose Intravenous Immunoglobulin in the Management of Myasthenia Gravis
Bonaventura et al.
Arch Intern Med 1987;147:207-211.
ABSTRACT
|
